BioSpace News Archive

Dr. Humphrey will oversee and drive clinical development efforts in TIO Bioventures’ oncology-focused portfolio companies

Industry Veteran Rachel W. Humphrey, M.D., Head of R&D at TIO Discovery, appointed as Board Member and Chief Medical Officer of Treadwell Therapeutics

Company to Host R&D Symposium for Investors/Analysts on Tuesday January 14, 2020 in San Francisco, CA from 6:30 to 8:00 am (Pacific Time)

New MGTA-117 ADC clinical candidate for conditioning demonstrates broad therapeutic index; advancing MGTA-117 to generate initial patient clinical data in 2021

Cortexyme, Inc. announced it is initiating an open-label extension study in the United States for its Phase 2/3 GAIN Trial of COR388 in subjects with mild to moderate Alzheimer’s disease.

Veravas, Inc. and Tymora Analytical Operations, LLC announced that they have entered into a strategic alliance to explore the integration of their respective technologies.

Adare Pharmaceuticals, Inc. and NLS Pharmaceutics Ltd. announced a collaboration to develop mazindol CR product candidates for the treatment of narcolepsy and Attention Deficit Hyperactivity Disorder.

BETonMACE Results Show 57% Hazard Reduction in Primary MACE for Patients on Apabetalone and New Oral Anti-Diabetic Treatments

Earlens Corporation, a medical technology company that has created the world’s first nonsurgical hearing solution that directly vibrates the eardrum, announced that they have entered into a strategic agreement with Verily, an Alphabet company, to develop next-generation capabilities for the Earlens® Contact Hearing Solution.

Bardy Diagnostics, Inc.,, a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, including the Carnation Ambulatory Monitor, the only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device, announced the appointment of Ed Vertatschitsch as Chief Operating Officer effective January 2, 2020.